Convos/ w/ Cardios / PCPs from Germany indicated Vazkepa could address a key unmet need in those hypertriglyceridemia / high CV risk...Work supports Roanna's view that Vazkepa could achieve ~$1B peak sales in Europe. Convos underscore key points from prior EU survey suggesting that: (1) many HTG patients remain at high risk of having a major adverse cardiac event; (2) physicians like Vazkepa’s ability to meaningfully lower triglyceride levels and CV risk; (3) initial Vazkepa Germany pricing of €200/mo has not deterred prescribers. Reit OP. $10 PT.
Market Data 
Markets 
AI
